CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19B-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang UniversityShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Nephritis +[8] 
Inactive IndicationsLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A